Edition:
India

Alexion Pharmaceuticals Inc (ALXN.OQ)

ALXN.OQ on NASDAQ Stock Exchange Global Select Market

108.05USD
21 Nov 2017
Change (% chg)

$-0.44 (-0.41%)
Prev Close
$108.49
Open
$109.08
Day's High
$109.37
Day's Low
$107.90
Volume
603,048
Avg. Vol
606,763
52-wk High
$149.17
52-wk Low
$96.18

Chart for

About

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company's clinical development programs include Soliris (eculizumab... (more)

Overall

Beta: 1.28
Market Cap(Mil.): $31,536.07
Shares Outstanding(Mil.): 223.19
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.15 16.44
EPS (TTM): -- -- --
ROI: -- 14.99 10.62
ROE: -- 16.33 14.20

BRIEF-Alexion receives new Japanese patent for Soliris

* Alexion receives new Japanese patent for Soliris® (eculizumab), extending patent protection into 2027 and strengthening global patent portfolio Source text for Eikon: Further company coverage:

06 Nov 2017

BRIEF-Alexion reports Q3 non-GAAP earnings per share of $1.44

* Q3 earnings per share view $1.32 -- Thomson Reuters I/B/E/S

26 Oct 2017

RPT-BRIEF-Alexion announces interim analysis from phase 3 open-label extension study of Soliris

* Interim analysis from phase 3 open-label extension study shows sustained benefits of Soliris (Eculizumab) treatment for patients with refractory generalized myasthenia gravis

14 Sep 2017

BRIEF-Interim analysis from phase 3 open-label extension study of Soliris

* Interim analysis from phase 3 open-label extension study shows sustained benefits of Soliris (Eculizumab) treatment for patients with refractory generalized myasthenia gravis

14 Sep 2017

Alexion Pharma to lay off 20 percent of workforce

Alexion Pharmaceuticals Inc said on Tuesday it would lay off about 20 percent of its workforce and sharpen its focus on its core rare disease drugs business, as it looks to restore investor confidence.

12 Sep 2017

UPDATE 2-Alexion Pharma to lay off 20 pct of workforce

* Drugmaker's shares down slightly (Adds details, analyst comment, updates share price)

12 Sep 2017

Drugmaker Alexion to cut 20 pct of jobs

Sept 12 U.S. drugmaker Alexion Pharmaceuticals Inc said on Tuesday it would lay off about 20 percent of its global workforce in an effort to cut spending.

12 Sep 2017

BRIEF-Alexion to reduce 20 pct of its global workforce

* Alexion announces restructuring to advance corporate strategy

12 Sep 2017

BRIEF-Alexion receives three U.S. Patents for Soliris (eculizumab), extending patent protection into 2027

* Alexion receives three U.S. Patents for Soliris (eculizumab), extending patent protection into 2027

16 Aug 2017

BRIEF-Third Point LLC takes share stake in Blackrock Inc, Alexion Pharmaceuticals

* Third Point LLC takes share stake of 1.6 million shares in Blackrock Inc - SEC filing‍​

12 Aug 2017

Competitors

Earnings vs. Estimates